RC
EGRX

RBF Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

RBF Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-143,078
Closed -$534K – 616
2024
Q3 		$534K Buy
143,078
+14,991
+12% +$71.5K 0.03% 404
2024
Q2 		$717K Buy
+128,087
New +$558K 0.04% 327

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

RBF Capital's EGRX Position: Q4 2024 in Review

RBF Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 143,078 shares — an estimated $534K sold.

RBF Capital first reported a position in EGRX in Q2 2024 and held it in 2 quarters. The position peaked at $717K in Q2 2024. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • RBF Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • RBF Capital sold 143,078 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $534K.
  • RBF Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2024 and held it in 2 quarters.
  • RBF Capital's Eagle Pharmaceuticals, Inc. position peaked at $717K in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on RBF Capital's 13F filing for Q4 2024, filed 14 Feb 2025.